Filing Flows › Health Care › Sarepta Therapeutics (SRPT)
Sarepta Therapeutics (SRPT) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Sarepta Therapeutics (SRPT) Q3 2026 earnings results →
Q3 2026 Revenue down 4% year over year to $381M · 7¢ of every $1 of revenue lost · operating margin -2.4%
Sarepta Therapeutics made $381M in Q3 2026 (-4% Y/Y): Pmo Products $240M, Elevidys $83.5M, Other revenues $57.6M. Operating margin -2.4%, net loss $28.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $381.4M in Q3 2026, down 5% year over year and down 5% from the previous quarter. Pmo Products was the largest line at 63% of revenue. Elevidys lost $48.0M year over year (down 37%), 267% of the total change.
Operating costs exceeded revenue by $9.0M, an operating margin of -2.4%. The fastest-growing cost line was Other operating costs (+1494%). The quarter ended with a net loss of $28.5M, wider than the previous quarter's $4.9M loss. Net interest and other expense of $16.7M was the main reason.
Operating cash flow was $60.0M. Non-cash charges added back $5.9M of depreciation and amortization and $26.7M of share-based compensation. Working capital and other items added $55.8M. Capital expenditures of $2.9M left free cash flow of $57.0M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $381M | -4% | -2.4% | −$28.5M | $60.0M |
| Q2 2026 | 10-Q | Aug 5, 2026 | $401M | -34% | 3.3% | −$4.9M | $197M |
| Q1 2026 | 10-Q | May 6, 2026 | $731M | -2% | 49.0% | $331M | −$203M |
| Q4 2025 | 10-K | Mar 2, 2026 | $443M | -33% | -92.9% | −$283M | $131M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $399M | -14% | -25.9% | −$180M | −$14.6M |
| Q2 2025 | 10-Q | Aug 6, 2025 | $611M | +68% | 18.9% | $197M | $261M |
| Q1 2025 | 10-Q | May 6, 2025 | $745M | +80% | -40.3% | −$448M | −$583M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Sarepta Therapeutics
We are a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Applying our proprietary, differentiated and innovative technologies, and through collaborations with our strategic partners, we have developed multiple approved products for the treatment of Duchenne muscular dystrophy ("Duchenne") and are developing potential therapeutic candidates for a broad range of diseases and disorders, including Duchenne and LGMD.
In its own words, from its 10-K, filed Mar 2, 2026.
Sarepta Therapeutics against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -4% against the peers' median +7%. Operating margin: -2.4% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Q3 2026 | $381M | -4% | -2.4% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Sarepta Therapeutics 10-Q on SEC EDGAR · CIK 873303 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns SRPT and who is buying
More on SRPT
- How Sarepta Therapeutics makes money: revenue by segment
- Sarepta Therapeutics next earnings date and what analysts expect
- Sarepta Therapeutics stock forecast, price target and fair value
- Who owns Sarepta Therapeutics stock: holders, funds and Congress trades
- Sarepta Therapeutics guidance and outlook
- Is Sarepta Therapeutics a takeover target? LBO and rumors
- Sarepta Therapeutics recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results